Applicant, as named in the Orange Book

Array Biopharma Inc

Next listed expiry: Braftovi on 5 Aug 2033. 2 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Braftovi encorafenib	encorafenib	210496	5 Aug 2033	patent, carve-out possible
Mektovi binimetinib	binimetinib	210498	18 Oct 2033	patent